Anurag agarwal

Anurag Agarwal is a Principal at Osage University Partners. He joined OUP in 2017, and since then, he has focused on life science investments. He has been involved with OUP’s investment in several portfolio companies, including Dracen Pharmaceuticals, Cyteir Therapeutics, Homology Medicines, and others. Anurag has also served as a board observer for Dracen Pharmaceuticals. Prior to joining OUP, Anurag worked as a consultant at The Boston Consulting Group, where he advised healthcare and private equity companies on corporate growth strategy, business development, portfolio management, and M&A projects.

Anurag's professional career is backed by a PhD from Washington University School of Medicine in Molecular Cell Biology and a B.Tech in Biotechnology from Indian Institute of Technology, Madras. During his graduate school, he founded SCIMALS to provide scientific and market due diligence services for life science VCs and angel investors. Anurag also advised biotech start-ups in St. Louis area on market research, competitive intelligence, and asset prioritization.

His strong educational background and work experience make him a proficient professional in life science investments. Anurag's expertise also extends to corporate growth strategy, business development, portfolio management, M&A projects, and providing scientific and market due diligence services for life science VCs and angel investors.